Research around beta 2-glycoprotein I: a major target for antiphospholipid antibodies

Autoimmunity. 2005 Aug;38(5):377-81. doi: 10.1080/08916930500124312.

Abstract

Beta2-glycoprotein I (beta2GPI), a phospholipid-binding protein, is one of the major target antigens for antiphospholipid antibodies (aPL) found in patients with antiphospholipid syndrome (APS). Thrombophilic disorders in APS patients are strongly associated with aPL, and their pathogenic properties depend on the presence of beta2GPI. Procoagulant cell stimulation by aPL, via beta2GPI, is one of the most plausible mechanisms of thrombosis in APS, and p38 mitogen activated protein kinase (MAPK) pathway plays a crucial role in such activation. beta2GPI is proteolytically cleaved in domain V by activated factor X or plasmin, leading to the generation of the nicked form of beta2GPI. Recently, increasing attention is focused on the role of nicked-beta2GPI as a regulator of extrinsic fibrinolysis pathway.

Publication types

  • Review

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Antibodies, Antiphospholipid / metabolism*
  • Antibodies, Antiphospholipid / therapeutic use*
  • Autoimmune Diseases / immunology*
  • Autoimmune Diseases / therapy*
  • Glycoproteins / metabolism*
  • Humans
  • Molecular Sequence Data
  • Phospholipids / metabolism*
  • Protein Binding / immunology
  • beta 2-Glycoprotein I

Substances

  • Antibodies, Antiphospholipid
  • Glycoproteins
  • Phospholipids
  • beta 2-Glycoprotein I